Comparison
NMN vs. Nicotinamide Riboside (NR)
NMN or NR – which NAD+ precursor is better supported?
The short answer
Neither has shown a clinical benefit in humans. Both reliably raise NAD+ levels in the blood – that is a surrogate marker, not an outcome. There are more placebo-controlled studies on nicotinamide riboside, and a critical review in Science Advances 2023 concludes that most clinical endpoints remained unaffected; the only replicated finding is a reduction in inflammatory markers. NMN also has a regulatory problem: since 2022, the US authority no longer classifies it as a dietary supplement because it is being studied as a drug candidate. If you choose between the two, you are choosing between two substances whose benefit is an open question.
The numbers side by side
| Axis | NMN | Nicotinamide riboside (NR) | Difference |
|---|---|---|---|
| Human evidenceHow much data from humans there is, and how good it is | 3 | 5 | Nicotinamide riboside better studied |
| MechanismHow well the chain of action is understood | 6 | 6 | even |
| Safety dataHow well safety has been studied – not how safe it is | 5 | 6 | Nicotinamide riboside better studied |
| Hype gap10 means: the marketing stays in line with the data | 2 | 3 | Nicotinamide riboside closer to the data |
| Track record of useHow much documented use in humans there is – does not measure whether it works | 5 | 5 | even |
| Assessment | Hype far ahead of evidence · Thin human evidence | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules. It is not a scientific rating, not the consensus of a medical society and not a medical recommendation.
Why these numbers
NMN
In humans there are small studies with surrogate markers, no endpoint data; the NAD pathway is plausible, but the increase in tissue is weakly supported. Safety data are short-term only – and hardly any longevity product is more overhyped.
Nicotinamide riboside (NR)
An unusually large number of RCTs for a longevity supplement – with a clear pattern: NAD+ levels in the blood rise reliably, and that has been reproduced. A critical review (Science Advances 2023) concludes that most clinical endpoints – insulin sensitivity, glucose control, body composition, blood pressure – remained unaffected; the only replicated finding is a reduction in inflammatory markers. For aging itself, there are no endpoint data in humans. Safety has been properly studied over weeks to months, including in a high-dose study in Parkinson's disease.
Frequently asked questions
Do NMN and NR really raise NAD+ levels?
Yes, that is the best-supported part. Several placebo-controlled studies show a measurable rise in NAD+ levels in the blood. What remains open is whether a health benefit follows from this – clinical endpoints such as insulin sensitivity, blood pressure and body composition remained largely unchanged in the studies.
Why is NMN no longer allowed as a supplement in the US?
The US authority no longer classifies a substance as a dietary supplement once it is in clinical testing as a drug candidate. That is exactly the case with NMN. In the EU, NMN is not authorized as a novel food.
What would proof of benefit require?
A randomized trial with a hard endpoint – mortality, disease incidence, functional capacity – over years rather than weeks. Such studies do not exist for either substance.
See all 255 ratings in the ranking
Information only, not medical advice and no usage or dosage recommendation. Prescription and unapproved drugs belong in the hands of a physician.